Results 141 to 150 of about 31,387 (227)

Comprehensive assessment of unfolded protein response and its association with tumor progression in pan‐cancer

iMetaOmics, Volume 3, Issue 1, March 2026.
Schematic of the study design. In this study, we developed a comprehensive unfolded protein response (UPR) gene signature and applied it to systematically characterize the UPR landscape across multiple cancer types. By integrating bulk and single‐cell transcriptomic data, we revealed substantial inter‐ and intra‐tumoral heterogeneity in UPR activity ...
Xinyu Yang, Faming Zhao, Jing Yang, Xinran Xia, Liwei Chen, Peng Zeng, Liang Chen, Yanxia Hu, Xia Sheng   +8 more
wiley   +1 more source

A Review of the Latest Evidence on Prognostic Factors in Locally Advanced and Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors. [PDF]

Medicina (Kaunas)
Cojocaru I, Guliciuc M, Cojocaru E, Serban C, Pascaru G, Borz MB, Schitcu VH, Tise AI, Osoianu I, Rebegea LF.   +9 more
europepmc   +1 more source

RNA Regulatory Networks: Key Hubs in the Panorama of Cancer and Emerging Therapeutic Targets

MedComm, Volume 7, Issue 3, March 2026.
RNA regulatory networks play a crucial role in the initiation and progression of cancer through various modes of RNA interactions. Notably, circulating RNAs have emerged as potential biomarkers, while targeted interventions in RNA regulatory networks facilitate precise therapeutic strategies. ABSTRACT Cancer is a global health challenge. The initiation
Xuan Yin, Zengkan Du, Shuya Jiang, Yan Liao, Changli Wang, Jiaqi Li, Haoling Zhang, Ting‐Ting Wei, Wangzheqi Zhang, Zui Zou   +9 more
wiley   +1 more source

First-line enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma-commentary on patient-reported outcomes in EV-302. [PDF]

Transl Androl Urol
Liedberg F, Ståhl O, Bobjer J.
europepmc   +1 more source

Obstructive Hydrocephalus in Metastatic Urothelial Carcinoma

The American Journal of Medicine
Ami Schattner, Livnat Uliel, Ina Dubin
openaire   +2 more sources

Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Companion diagnostics use biomarker‐based assays to stratify patients for precision therapies, improving outcomes while reducing ineffective treatment and side effects. This review summarizes the evolution, regulatory landscape, clinical applications, and technological platforms of CDx, highlighting their role in biomarker‐driven precision therapy.
Yuesong Wu, Rou Xue, Xiangwen Luo, Jiangnan Liao, Zongbo Zhang, Jinhai Deng, Teng Liu, Xin Li, Zhe‐Sheng Chen, Mingzhu Yin   +9 more
wiley   +1 more source

Outcomes and Management of Dermatologic Toxicity Following Enfortumab Vedotin Rechallenge in Patients With Metastatic Urothelial Carcinoma: A Retrospective Single-Center Study. [PDF]

Cancer Rep (Hoboken)
Kawahara T, Nagumo Y, Yamaguchi A, Hamada K, Tanuma K, Nitta S, Shiga M, Ikeda A, Kandori S, Hoshi A, Nishiyama H.   +10 more
europepmc   +1 more source

Early Cancer Detection: What's Going on and What's Next

MedComm, Volume 7, Issue 3, March 2026.
Multicancer early detection (MCED) platforms have emerged as a promising strategy for the safe and effective early detection of multiple cancer types, with the potential to reduce metastatic burden and improve clinical outcomes, particularly for aggressive malignancies that lack effective population‐level screening.
Emma Di Carlo
wiley   +1 more source

Chromatin Accessibility in Cancer: Biological Functions, Mechanisms, Therapeutic Potential, and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Cancer remains the leading cause of mortality worldwide, and drug resistance further underscores the urgent need for innovative therapeutic strategies. Chromatin, a stable yet highly dynamic nucleoprotein complex, serves as the primary carrier of genetic material in eukaryotic cells.
Wentao Xia, Min Jiang, Yefei Huang, Kun Ding, Yansu Chen   +4 more
wiley   +1 more source

Nivolumab plus gemcitabine-cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial. [PDF]

ESMO Open
Bedke J, van der Heijden MS, Sonpavde G, Galsky MD, Liao W, Shi L, Blum SI, Mitra S, Patel MY, Powles T.   +9 more
europepmc   +1 more source